Trillium Therapeutics Inc. — Form D

Trillium Therapeutics Inc. of MISSISSAUGA, A6, a company, filed a Form D exempt-offering notice with the SEC on 2017-12-12. The offering totals $20.0M, of which $20.0M was reported sold. Industry: Pharmaceuticals.

Offering

Filed: 2017-12-12
Form: D
Accession: 0001062993-17-005233
Industry: Pharmaceuticals
Exemptions: 06b
Total offering: $20.0M
Amount sold: $20.0M
Investors: 2
Date of first sale: 2017-12-01
Security types: equity
Revenue range: Decline to Disclose
SEC file number: 021-300546

Issuer

Name: Trillium Therapeutics Inc.
CIK: 0001616212
Entity type: Corporation
Jurisdiction: ONTARIO, CANADA
Address: 2488 DUNWIN DRIVE, MISSISSAUGA, A6, L5L 1J9
Phone: (416) 595-0627

Officers, directors & promoters (13)

Name	Role	Location
Luke Beshar	Director	Mississauga, A6
Henry Frieson	Director	Mississauga, A6
Robert Kirkman	Director	Los Angeles, CA
Michael Moore	Director	SAN FRANCISCO, CA
Thomas Reynolds	Director	San Diego, CA
Niclas Stiernholm	Director	Mississauga, A6
Calvin Stiller	Director	Mississauga, A6
Helen Tayton-Martin	Director	Mississauga, A6
James Parsons	Executive Officer	Mississauga, A6
Penka Petrova	Executive Officer	Mississauga, A6
Eric Sievers	Executive Officer	Mississauga, A6
Niclas Stiernholm	Executive Officer	Mississauga, A6
Robert Uger	Executive Officer	Mississauga, A6

More